CN109985030B - 醌式查尔酮化合物在制备抗肿瘤药物中的应用 - Google Patents

醌式查尔酮化合物在制备抗肿瘤药物中的应用 Download PDF

Info

Publication number
CN109985030B
CN109985030B CN201711309136.0A CN201711309136A CN109985030B CN 109985030 B CN109985030 B CN 109985030B CN 201711309136 A CN201711309136 A CN 201711309136A CN 109985030 B CN109985030 B CN 109985030B
Authority
CN
China
Prior art keywords
tumor
cells
ifn
formulation
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201711309136.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN109985030A (zh
Inventor
黄波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guchong Pharmaceutical Beijing Co ltd
Jichong Beijing Pharmaceutical Co ltd
Original Assignee
Guchong Pharmaceutical Beijing Co ltd
Life-Garden Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guchong Pharmaceutical Beijing Co ltd, Life-Garden Biotech filed Critical Guchong Pharmaceutical Beijing Co ltd
Priority to CN201711309136.0A priority Critical patent/CN109985030B/zh
Priority to EP18889684.9A priority patent/EP3675841B1/en
Priority to JP2020552072A priority patent/JP6987271B2/ja
Priority to PCT/CN2018/075163 priority patent/WO2019114125A1/en
Priority to ES18889684T priority patent/ES2979333T3/es
Publication of CN109985030A publication Critical patent/CN109985030A/zh
Priority to US16/897,733 priority patent/US10988429B2/en
Application granted granted Critical
Publication of CN109985030B publication Critical patent/CN109985030B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/02—Quinones with monocyclic quinoid structure
    • C07C50/06—Quinones with monocyclic quinoid structure with unsaturation outside the quinoid structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/30—Quinones containing groups having oxygen atoms singly bound to carbon atoms with polycyclic non-condensed quinoid structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201711309136.0A 2017-12-11 2017-12-11 醌式查尔酮化合物在制备抗肿瘤药物中的应用 Active CN109985030B (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN201711309136.0A CN109985030B (zh) 2017-12-11 2017-12-11 醌式查尔酮化合物在制备抗肿瘤药物中的应用
EP18889684.9A EP3675841B1 (en) 2017-12-11 2018-02-02 A novel quinochalcone compound and uses thereof for treating cancer or inflammation
JP2020552072A JP6987271B2 (ja) 2017-12-11 2018-02-02 新規キノカルコン化合物、及びがん又は炎症を治療するためのその用途
PCT/CN2018/075163 WO2019114125A1 (en) 2017-12-11 2018-02-02 A novel quinochalcone compound and uses thereof for treating cancer or inflammation
ES18889684T ES2979333T3 (es) 2017-12-11 2018-02-02 Un nuevo compuesto de quinochalcona y usos del mismo para tratar el cáncer o la inflamación
US16/897,733 US10988429B2 (en) 2017-12-11 2020-06-10 Quinochalcone compound and uses thereof for treating cancer or inflammation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711309136.0A CN109985030B (zh) 2017-12-11 2017-12-11 醌式查尔酮化合物在制备抗肿瘤药物中的应用

Publications (2)

Publication Number Publication Date
CN109985030A CN109985030A (zh) 2019-07-09
CN109985030B true CN109985030B (zh) 2021-07-06

Family

ID=66819884

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711309136.0A Active CN109985030B (zh) 2017-12-11 2017-12-11 醌式查尔酮化合物在制备抗肿瘤药物中的应用

Country Status (6)

Country Link
US (1) US10988429B2 (enExample)
EP (1) EP3675841B1 (enExample)
JP (1) JP6987271B2 (enExample)
CN (1) CN109985030B (enExample)
ES (1) ES2979333T3 (enExample)
WO (1) WO2019114125A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114409522B (zh) * 2022-03-01 2023-08-15 贵州省天然产物研究中心 一种查尔酮衍生物及其制备方法与用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085219A (zh) * 2014-05-22 2015-11-25 中国医学科学院药物研究所 A环具有异戊烯基的醌式查尔酮化合物，制法与抗炎活性
CN105085218A (zh) * 2014-05-22 2015-11-25 中国医学科学院药物研究所 一类a环具有甲基的醌式查尔酮化合物，制法与抗炎活性

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013054998A1 (ko) * 2011-10-13 2013-04-18 건국대학교 산학협력단 신규한 칼콘 유도체 및 이를 유효성분으로 하는 항암제 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085219A (zh) * 2014-05-22 2015-11-25 中国医学科学院药物研究所 A环具有异戊烯基的醌式查尔酮化合物，制法与抗炎活性
CN105085218A (zh) * 2014-05-22 2015-11-25 中国医学科学院药物研究所 一类a环具有甲基的醌式查尔酮化合物，制法与抗炎活性

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Antitumor Agents 259. Design, Syntheses, and Structure-Activity Relationship Study of Desmosdumotin C Analogs;Kyoko Nakagawa-Goto等;《Journal of Medicinal Chemistry》;20071231;第50卷(第14期);第3354-3358页 *
Antitumor agents 283. Further elaboration of Desmosdumotin C analogs as potent antitumor agents: Activation of spindle assembly checkpoint as possible mode of action;Kyoko Nakagawa-Goto等;《Bioorganic & Medicinal Chemistry》;20110115;第19卷(第5期);第1816-1822页 *
毛叶假鹰爪素C 衍生物的合成、构效关系分析及其抗肿瘤活性研究;向卓等;《中国药学杂志》;20170831;第52卷(第16期);第1387-1392页 *

Also Published As

Publication number Publication date
EP3675841C0 (en) 2024-04-10
EP3675841A4 (en) 2021-06-09
US10988429B2 (en) 2021-04-27
ES2979333T3 (es) 2024-09-25
JP2021505691A (ja) 2021-02-18
EP3675841A1 (en) 2020-07-08
JP6987271B2 (ja) 2021-12-22
US20200377439A1 (en) 2020-12-03
CN109985030A (zh) 2019-07-09
WO2019114125A1 (en) 2019-06-20
EP3675841B1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
US10821127B2 (en) Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient
US12178792B2 (en) Pharmaceutical composition and use thereof in preparing drug for treating tumor multi-drug resistance
WO2020243911A1 (zh) Nad+和/或nad+抑制剂和/或nad+激动剂的用途及其联合制剂
JP2018533560A (ja) 癌を治療するための併用療法
US20220133675A1 (en) Phorbol ester compositions and methods of use for treating or reducing the duration of cytopenia
KR101902355B1 (ko) 데시타빈 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 골수유래억제세포 저해용 조성물
KR20190105602A (ko) Htlv-1 관련 척수증을 치료하는 것에 사용하기 위한 의약 조성물
AU2017309221A1 (en) Application of phosphodiesterase 4 inhibitor ZL-n-91 in preparation of medicament for treating prostate cancer proliferation and metastasis
CN118593502A (zh) 一种预防或治疗tp53突变双打击淋巴瘤的联合用药物组合物及其应用
EP4427753A1 (en) Immunomodulator composition comprising azvudine
CN108295085B (zh) 原薯蓣皂苷在制备抗耐药性骨肉瘤药物中的应用
CN117883450A (zh) 一种预防或治疗弥漫性大b细胞淋巴瘤的联合用药物组合物及其应用
JP2019504894A (ja) 肺がんの増殖および転移に対する薬物の調製におけるＰＤＥ４阻害剤ＺＬ−ｎ−９１の使用
CN109966275B (zh) 醌式查尔酮化合物在制备抗肿瘤药物中的应用
JP6373252B2 (ja) オーロラキナーゼ阻害薬を使用する癌の治療方法
CN113663081A (zh) 千层纸素和pd-1/pd-l1抑制剂在制备肝癌治疗药物中的应用
CN119770495A (zh) 一种改善或治疗滤泡淋巴瘤的联合用药物组合物及其应用
WO2021023291A1 (zh) 原黄素在肺癌治疗中的应用
CN109568313B (zh) 一种抗肿瘤联合用药物及其在制备抗癌药物中的应用
TWI870704B (zh) 治療表達pd-l1之癌症的方法
WO2017064558A1 (ja) 新規免疫賦活化剤
CN109420167B (zh) 一种治疗肿瘤的联合用药物
US20200369607A1 (en) Combinations of irs/stat3 dual modulators and anti pd-1/pd-l1 antibodies for treating cancer
CN116077643A (zh) 治疗和/或预防肺癌的联合用药物及应用
EP3675841B1 (en) A novel quinochalcone compound and uses thereof for treating cancer or inflammation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20200826

Address after: Room B307, building 1, No. 29, life Garden Road, Huilongguan town, Changping District, Beijing 100096 (Changping Demonstration Park)

Applicant after: Guchong Pharmaceutical (Beijing) Co.,Ltd.

Address before: 101400 Beijing Huairou North Fang Yuhua Garden Area 2-1-1401

Applicant before: LIFE-GARDEN BIOTECH

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Room 609, No. 6 North Row, No. 28 Courtyard, Dongbeiwang Village South, Dongbeiwang Township, Haidian District, Beijing, 100193

Patentee after: Guchong Pharmaceutical (Beijing) Co.,Ltd.

Address before: 100096 room B307, building 1, 29 shengshengyuan Road, Huilongguan town, Changping District, Beijing (Changping Demonstration Park)

Patentee before: Guchong Pharmaceutical (Beijing) Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230504

Address after: Room 176, 1st Floor, Building B, Entrepreneurship Development Center, No. 12 Yushun Road, Yufa Town, Daxing District, Beijing 102600 (cluster registration)

Patentee after: Jichong (Beijing) Pharmaceutical Co.,Ltd.

Address before: Room 609, No. 6 North Row, No. 28 Courtyard, Dongbeiwang Village South, Dongbeiwang Township, Haidian District, Beijing, 100193

Patentee before: Guchong Pharmaceutical (Beijing) Co.,Ltd.